Apogee Therapeutics, Net Worth
Apogee Therapeutics, Net Worth Breakdown | APGE |
Apogee Therapeutics, Net Worth Analysis
Apogee Therapeutics,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Apogee Therapeutics,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Apogee Therapeutics,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Apogee Therapeutics,'s net worth analysis. One common approach is to calculate Apogee Therapeutics,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Apogee Therapeutics,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Apogee Therapeutics,'s net worth. This approach calculates the present value of Apogee Therapeutics,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Apogee Therapeutics,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Apogee Therapeutics,'s net worth. This involves comparing Apogee Therapeutics,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Apogee Therapeutics,'s net worth relative to its peers.
To determine if Apogee Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Apogee Therapeutics,'s net worth research are outlined below:
| Apogee Therapeutics, generated a negative expected return over the last 90 days | |
| Apogee Therapeutics, has high historical volatility and very poor performance | |
| Apogee Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (83.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apogee Therapeutics, generates negative cash flow from operations | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Apogee Therapeutics to Host Inaugural Virtual RD Day on December 2, 2024 |
Apogee Therapeutics, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Apogee Therapeutics, Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apogee Therapeutics,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Apogee Therapeutics,'s market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.44 B.Market Cap |
|
Project Apogee Therapeutics,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.20) | (0.21) |
When accessing Apogee Therapeutics,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Apogee Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Apogee Therapeutics,'s profitability and make more informed investment decisions.
Please note, the presentation of Apogee Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Apogee Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Apogee Therapeutics,'s management manipulating its earnings.
Evaluate Apogee Therapeutics,'s management efficiency
Apogee Therapeutics, has return on total asset (ROA) of (0.1852) % which means that it has lost $0.1852 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2565) %, meaning that it created substantial loss on money invested by shareholders. Apogee Therapeutics,'s management efficiency ratios could be used to measure how well Apogee Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.26. As of November 22, 2024, Total Assets is expected to decline to about 304.4 M. In addition to that, Non Current Assets Total is expected to decline to about 1.6 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.01 | |
| Tangible Book Value Per Share | 0.02 | 0.01 | |
| Enterprise Value Over EBITDA | -7.5 K | -7.9 K | |
| Price Book Value Ratio | 1.8 K | 1.9 K | |
| Enterprise Value Multiple | -7.5 K | -7.9 K | |
| Price Fair Value | 1.8 K | 1.9 K | |
| Enterprise Value | 831.5 M | 739.1 M |
At Apogee Therapeutics,, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Return On Equity (0.26) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apogee Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apogee Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apogee Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Apogee Therapeutics, Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 6th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Apogee Therapeutics, Earnings per Share Projection vs Actual
Apogee Therapeutics, Corporate Management
| Carl MD | Chief Officer | Profile | |
| Noel Kurdi | Vice Relations | Profile | |
| Drew Badger | Senior Toxicology | Profile | |
| Monica Forbes | Senior Finance | Profile | |
| Matthew JD | General Counsel | Profile | |
| Jane Henderson | Chief Officer | Profile | |
| Dan Mulreany | Senior Strategy | Profile |
Already Invested in Apogee Therapeutics, Common?
The danger of trading Apogee Therapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apogee Therapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apogee Therapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apogee Therapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apogee Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.